Syros Pharmaceuticals

General Information
Business:

We are a biopharmaceutical company pioneering the understanding of the region of the genome controlling the activation and repression of genes. Our goal is to advance a new wave of medicines to control the expression of disease-driving genes. We have built a proprietary gene control platform designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, we believe that our gene control platform has broad potential to create medicines that achieve profound and durable benefit across therapeutic areas and a range of diseases.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 49
Founded: 2011
Contact Information
Address 620 Memorial Drive, Suite 300, Cambridge, MA 02139, US
Phone Number (617) 744-1340
Web Address http://www.syros.com
View Prospectus: Syros Pharmaceuticals
Financial Information
Market Cap $284.5mil
Revenues $0.3 mil (last 12 months)
Net Income $-35.8 mil (last 12 months)
IPO Profile
Symbol SYRS
Exchange NASDAQ
Shares (millions): 4.0
Price range $12.50 - $12.50
Est. $ Volume $50.0 mil
Manager / Joint Managers Cowen and Company/ Piper Jaffray
CO-Managers JMP Securities/ Wedbush PacGrow
Expected To Trade: 6/30/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change